Full-Time

Scientist – Computational Biology

Posted on 10/31/2025

Colossal

Colossal

201-500 employees

Gene editing for de-extinction of megafauna

No salary listed

Dallas, TX, USA

In Person

Category
Biology & Biotech (5)
, , , ,
Required Skills
Bash
Microsoft Azure
Python
MySQL
R
Git
Ruby
Java
Postgres
SAP Products
AWS
Perl
MongoDB
Google Cloud Platform
Requirements
  • Two years of bioinformatics experience in the following areas: Comparative Genomics, Functional Genomics / Multi-Omics, Molecular Evolution, or Applied AI in Genomics.
  • Familiarity in producing and curating genomic resources (e.g., reference genomes and gene annotations) for vertebrate organisms, especially in non-traditional model systems.
  • Experience in the development of models to predict biological results or gene function, including variant detection, functional predictions, and genotype/phenotype relationships.
  • Capable of leveraging knowledge across multiple levels of biological organization to validate the outputs of complex, integrative analyses.
  • Demonstrated 2 years of experience with scripting languages, including but not limited to: Python, R, Perl, Ruby, Java, and BASH.
  • Ability to write and run custom bioinformatics scripts using existing published tools and occasionally tools developed to summarize the results in a digestible manner and deliver the information using established reporting procedures.
  • Proficiency with handling large-scale genomic data in an HPC (SGE, SLURM, PBS) Linux and/or cloud environment (e.g. AWS, Google Cloud, Azure).
  • Experience in using GIT version control software and maintaining well-documented, reproducible notebooks and workflows.
  • Ability to design and maintain databases (MySQL, PostgreSQL, MongoDB) and connect with visual platforms to curate and share data with non-bioinformatics team members.
Responsibilities
  • Run data analysis with biological data
  • Run comparative, functional, and statistical genomics analysis
  • Develop new tools in R/Python for data analysis and visualization
  • Prepare reports and presentations to communicate findings to wet-bench biologists
Desired Qualifications
  • Calling germline and somatic sequence variants from high-coverage WGS, low-coverage WGS with imputation, and sequencing libraries from degraded or ancient DNA
  • Executing rigorous analyses of diverse functional epigenomics approaches (e.g., RNA-seq and ATAC-seq) and integrating multi-omics datasets to aid in understanding of gene expression regulation
  • Performing evolutionary and statistical genomics analyses, including population genetics analysis (e.g., runs of homozygosity and association mapping), genome-wide scans for evolutionary signatures and selective sweeps, and comparative genomics analyses associating genotype and phenotype (e.g., PAML inference of molecular evolution and phylogenetic regression)
  • Constructing, interpreting, and utilizing pangenome graphs, whole genome alignments, and gene homology relationships
  • Statistical planning and collaboration with laboratory scientists on designing well-powered experiments to generate useful multi-omics data sets
  • Developing or implementing AI/ML frameworks and systems biology networks (e.g., interpretable aka visible deep neural networks like GenNet) for genotype-to-phenotype and functional predictions
  • Understanding of precision gene editing technologies like CRISPR/Cas9 systems

Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.

Company Size

201-500

Company Stage

Series C

Total Funding

$625M

Headquarters

Austin, Texas

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquired ViaGen in 2025, birthed dire wolf pups Romulus, Remus, Khaleesi in April 2025.
  • Secured $60M UAE funding for Dubai BioVault preserving 10,000+ species genomes.
  • Spun out Astromech AI at $2B valuation, accelerating genomics with $120M avian funding.

What critics are saying

  • Dodo pipeline fails viability in 24-36 months, eroding confidence post-$120M raise.
  • Viagen scandals trigger FDA scrutiny on gene-edited animals within 12-18 months.
  • UAE BioVault seized amid tensions, locking out assets in 18-24 months.

What makes Colossal unique

  • Colossal pioneers CRISPR for de-extinction of woolly mammoth using elephant iPSCs.
  • First company to reprogram elephant iPSCs with Oct4, Sox2, Klf4 for mammoth traits.
  • Edits dunnart genomes with 300+ changes for thylacine revival, most edited animal cell.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Colossal who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Spending Account/Flexible Spending Account

401(k) Company Match

Paid Parental Leave

Education Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Business Journals
Apr 3rd, 2026
Dallas billionaire's second startup reaches $2B valuation with AI predicting diseases

A second startup from Dallas billionaire Ben Lamm has achieved unicorn status with a $2 billion valuation in its latest funding round. Lamm, who also co-founded and leads Colossal Biosciences, has seen his new venture reach the milestone valuation. The company focuses on predicting biology, evolution and diseases before they occur. This marks Lamm's second startup to surpass the $1 billion valuation threshold, following his success with Colossal Biosciences.

GamesBeat
Mar 26th, 2026
Colossal Biosciences spins out AI startup Astromech at $2B valuation

Colossal Biosciences, which is trying to bring back the wooly mammoth with genetics tech, has spun out its AI startup Astromech at a $2 billion valuation.

Dallas Innovates
Feb 3rd, 2026
Dallas-based Colossal gets $60M from UAE, will build modern 'Noah's Ark' in Dubai

Dallas-based Colossal Biosciences has secured $60 million from the United Arab Emirates to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future. The investment is part of Colossal's expanded Series C round, bringing total funding to over $615 million. The facility will house millions of samples representing more than 10,000 species, initially focusing on the 100 most imperiled species not currently preserved elsewhere. Using automated robotics, AI monitoring and cryopreservation technology, the project aims to create a backup system for Earth's biodiversity. The initiative addresses the threat that nearly half of Earth's species could face extinction by 2050. The Dubai facility will eventually form part of a global network of BioVaults. Visitors will observe scientists working in real time on DNA sequencing and cell line preservation.

PR Newswire
Feb 3rd, 2026
UAE partners with Colossal Biosciences in nine-figure deal to establish global species preservation vault

The UAE has partnered with Colossal Biosciences to establish a laboratory and BioVault at Dubai's Museum of the Future, positioning the nation as a global leader in conservation and biodiversity protection. The initiative represents a nine-figure investment, with the UAE contributing to Colossal's recent funding round. The Colossal BioVault will preserve genetic material from over 10,000 species, initially focusing on the 100 most imperiled species not currently banked elsewhere. The facility will use automated robotics, AI monitoring and proprietary cryopreservation technology to store millions of samples. The project addresses the biodiversity crisis, with nearly half of Earth's species potentially facing extinction by 2050. The BioVault will serve as a research hub, generating genomic data and reference genomes whilst operating as a live laboratory where visitors can witness preservation work in real time.

Business Wire
Nov 5th, 2025
Colossal Biosciences Acquires Viagen, the Leader in Animal Cloning

Colossal Biosciences, the world’s de-extinction company, today announced its acquisition of Viagen Pets and Equine, the global leader and expert in animal cl...

INACTIVE